GleamWall
中文EN

PLSE PULSE BIOSCIENCES, INC.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1625101 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,637.2%
TTM net income YoY-12.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin26.8%
Operating margin-5,821.1%
Net margin-5,603.9%
FCF margin-4,263.9%
EBITDA margin-5,796.8%

Returns

ROE-60.6%
ROA-54.0%
ROIC (approx.)-95.2%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets8.9%
Debt / equity0.00x
Current ratio14.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue24.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$350,000$0
Cost of revenue$539,000$0
Gross profit-$189,000$0
R&D expense$44.72M$32.34M
SG&A expense$32.03M$23.92M
Operating income-$76.94M-$56.26M
Pretax income$72.80M$53.60M
Income tax$0$0
Net income-$72.78M-$53.59M
EBITDA-$76.53M-$55.74M
EPS (basic)-1.08-0.92
EPS (diluted)——
Balance sheet
Cash & equivalents$80.73M$118.04M
Receivables$274,000$0
Inventory$136,000$0
Current assets$83.42M$119.45M
PP&E, net$1.05M$1.16M
Goodwill$2.79M$2.79M
Intangibles$575,000$1.22M
Total assets$94.54M$132.46M
Current liabilities$7.92M$10.05M
Total liabilities$13.88M$17.60M
Shareholders' equity$80.66M$114.86M
Shares outstanding67.84M65.93M
Cash flow statement
Operating cash flow-$54.12M-$36.34M
Capital expenditure$315,000$125,000
Free cash flow-$54.44M-$36.47M
Investing cash flow-$335,000-$125,000
Financing cash flow$17.15M$110.14M
Depreciation & amortization$406,000$512,000
Stock-based compensation$21.46M$13.59M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.